



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_292_26

You asked:

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions.

Please note for both questions, if a patient has received multiple injection/implants in the time period specified of January to April 2026, please count the total number of injections/implants that the Trust has administered. I.e. if a patient has received two injections/implants please count that as two.

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2026:

- **Aflibercept - Eylea**
- **Aflibercept - Biosimilar**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - including all Biosimilars**

Please find below a table populated with the data that Medicines Management are able to provide for January to April 2026:

Aflibercept - Eylea	457
Aflibercept - Biosimilar	119
Bevacizumab	21
Brolucizumab	0
Dexamethasone	63
Faricimab	1893
Fluocinolone acetonide	0
Ranibizumab - including all Biosimilars	19

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2026:

- **Aflibercept - Eylea**
- **Aflibercept - Biosimilar**
- **Bevacizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab - including all Biosimilars**

Please find below the table provided populated with the data that Medicines Management are able to provide for January to April 2026:

Treatment	Eye Condition			
	Wet Age-Related Macular Degeneration	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)	Non-infectious Uveitis (NIU)
Aflibercept - Eylea	257	73	131	n/a
Aflibercept - Biosimilar	67	18	32	n/a
Bevacizumab				n/a
Dexamethasone				
Faricimab	1177	404	311	n/a
Fluocinolone acetonide				
Ranibizumab - including all Biosimilars	5	0	*	n/a

Please note:

- For the grey shaded areas Medicines Management are unable to provide information, as our systems don't capture the necessary level of information. Therefore, we can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.
- Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.